

• RESULTS

The board of directors (the "Board") of Far East Pharmaceutical Technology Company Limited (the "Company") is pleased to announce the unaudited condensed consolidated interim results of the Company and its subsidiaries (the "Group") for the six months ended 31 December 2002 together with the comparative figures for the corresponding period in 2001 as follows:

• CONDENSED CONSOLIDATED INCOME STATEMENT

		Six months ended 31 December	
	Notes	2002 (Unaudited) HK\$'000	2001 (Unaudited) HK\$'000
TURNOVER	2 & 3	458,656	282,338
Cost of sales		<u>(276,642)</u>	<u>(177,873)</u>
GROSS PROFIT		182,014	104,465
Other revenue		3,127	1,150
Selling and distribution costs		(46,941)	(25,062)
Administrative expenses		(16,509)	(12,492)
Other operating expenses		<u>-</u>	<u>(3,563)</u>
PROFIT FROM OPERATING ACTIVITIES	4	121,691	64,498
Finance costs – interest expenses		-	(105)
Share of result of a jointly- controlled entity		<u>-</u>	<u>(131)</u>
PROFIT BEFORE TAXATION		121,691	64,262
Taxation	5	<u>(29,602)</u>	<u>(9,079)</u>
PROFIT BEFORE MINORITY INTERESTS		92,089	55,183
Minority interests		<u>(4,424)</u>	<u>(601)</u>
NET PROFIT FROM ORDINARY ACTIVITIES ATTRIBUTABLE TO SHAREHOLDERS		<u><u>87,665</u></u>	<u><u>54,582</u></u>
EARNINGS PER SHARE			
– Basic	7	<u><u>HK17.2 cents</u></u>	<u><u>HK15.3 cents</u></u>
– Diluted	7	<u><u>HK16.8 cents</u></u>	<u><u>HK14.1 cents</u></u>